Brief: Olverembatinib Granted Breakthrough Therapy Designation for the Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)
05/03/2025 23:03
March 5 (Reuters) - Ascentage Pharma Group International 6855.HK: OLVEREMBATINIB GRANTED BREAKTHROUGH THERAPY DESIGNATION FOR TREATMENT OF PHILADELPHIA CHROMOSOME-POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) Source text: ID:nGNX4nz2qD Further company coverage: 6855.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascentage Pharma International
See all newsBrief: Ascentage Pharma Group Says Lisaftoclax Granted Breakthrough Therapy Designation In China
China's Ascentage Pharma climbs as chairman buys shares on market
Brief: Ascentage Pharma Group International's Chairman Buys 38,630 Shares
Brief: Ascentage Pharma Group International Posts H1 Net Loss Attributable RMB816.7 Million
China's Ascentage Pharma H1 revenue rises 29% on Lisaftoclax ramp-up